


AMENDMENTS TO THE CLAIMS**IN THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as follows.

1. (Currently Amended) A compound of Formula (I):



(I)

wherein

a and b are, independently, equal to 0 wherein the value of 0 represents a direct bond;

W is-N(R₂)-,

wherein

R₂ is

- a) -alkyl;
- b) -L₃-D-G;
- c) -L₃-D-alkyl;
- d) -L₃-D-aryl;
- e) -L₃-D-heteroaryl;
- f) -L₃-D-cycloalkyl;
- g) -L₃-D-heterocyclyl;
- h) -L₃-D-arylene-alkyl;
- i) -L₃-D-alkylene-arylene-alkyl;
- j) -L₃-D-alkylene-aryl;
- k) -L₃-D-alkyl-G;
- l) -L₃-D-aryl-G;

- m) – L₃-D-heteroaryl-G;
- n) – L₃-D-cycloalkyl-G;
- o) – L₃-D-heterocyclyl-G;
- p) – L₃-D-arylene-alkyl-G;
- q) – L₃-D-alkylene-arylene-alkyl-G; or
- r) – L₃-D-alkylene-aryl-G;

wherein

L₃ is an –alkylene, –alkenylene, or alkynylene;


D is a direct bond, –CH₂–, –O–, –N(R₅)–, –C(O)–, –CON(R₅)–, –N(R₆)C(O)–, –N(R₆)CON(R₅)–, –N(R₅)C(O)O–, –OC(O)N(R₅)–, –N(R₆)SO₂–, –SO₂N(R₅)–, –C(O)–O–, –O–C(O)–, –S–, –S(O)–, –S(O₂)–, or –N(R₆)SO₂N(R₆)–, –N=N–, or –N(R₅)–N(R₆)–;

wherein

R₅ and R₆ are independently selected from the group consisting of:

–hydrogen, –alkyl, –aryl, –arylene-alkyl, –alkylene-aryl, and –alkylene-arylene-alkyl; and


G is hydrogen, –CN, –SO₃H, –P(O)(OH)₂, –P(O)(O-alkyl)(OH), –CO₂H,



–CO₂-alkyl, an acid isostere, –NR₇R₈, or ;

wherein

R₇ and R₈ are independently selected from the group consisting of:
 hydrogen, –alkyl, –L₄-E-alkyl, –L₄-E-aryl, –C(O)-alkyl, –C(O)-aryl, –SO₂-alkyl, –SO₂-aryl, and



wherein

R_9 , R_{10} , and R_{11} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

L_4 is a direct bond, -alkylene, -alkenylene, or -alkynylene;

E is a direct bond, $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{R}_{12})-$, $-\text{C}(\text{O})-$, $-\text{CON}(\text{R}_{12})-$, $-\text{N}(\text{R}_{12})\text{C}(\text{O})-$, $-\text{N}(\text{R}_{12})\text{CON}(\text{R}_{13})-$, $-\text{N}(\text{R}_{12})\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})\text{N}(\text{R}_{12})-$, $-\text{N}(\text{R}_{12})\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{R}_{12})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{O}-\text{C}(\text{O})-$, $-\text{S}-$, $-\text{S}(\text{O})-$, $-\text{S}(\text{O}_2)-$, $-\text{N}(\text{R}_{12})\text{SO}_2\text{N}(\text{R}_{13})-$, $-\text{N}=\text{N}-$, or $-\text{N}(\text{R}_{12})-\text{N}(\text{R}_{13})-$

wherein


R_{12} and R_{13} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

R_1 is

- a) -hydrogen;
- b) -fluoro;
- c) -chloro;
- d) -bromo;
- e) -iodo;
- f) -cyano;
- g) -alkyl;
- h) -aryl;
- i) -alkylene-aryl;

- j) -heteroaryl;
- k) -alkylene-heteroaryl;
- l) -cycloalkyl;
- m) -alkylene-cycloalkyl
- n) - heterocyclyl; or
- o) - alkylene-heterocyclyl;

L₁ is selected from the group consisting of:



wherein R₃ and R₄ are independently selected from the group consisting of: hydrogen, chloro, fluoro, bromo, alkyl, aryl, -alkylene-aryl, -cycloalkyl, -alkylene-cycloalkyl, -heterocyclyl, -alkylene-heterocyclyl, and -alkynylene;

Ar₁ is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -J-R₁₄;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;

- m) -cycloalkyl;
- n) -L₅-aryl;
- o) -L₅-arylene-aryl;
- p) -L₅-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -J-alkyl;
- t) -J-aryl;
- u) -J-alkylene-aryl;
- v) -J-arylene-alkyl;
- w) -J-alkylene-arylene-aryl;
- x) -J-arylene-arylene-aryl;
- y) -J-alkylene-arylene-alkyl;
- z) -L₅-J-alkylene-aryl;
- aa) -arylene-J-alkyl;
- bb) -L₅-J-aryl;
- cc) -L₅-J-heteroaryl;
- dd) -L₅-J-cycloalkyl;
- ee) -L₅-J-heterocyclyl;
- ff) -L₅-J-arylene-alkyl;
- gg) -L₅-J-alkylene-arylene-alkyl;
- hh) -L₅-J-alkyl;
- ii) -L₅-J-R₁₄; and
- jj) -arylene-J-R₁₄;

wherein

L₅ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

J is a direct bond, -CH₂-, -O-, -N(R₁₅)-, -C(O)-, -CON(R₁₅)-, -N(R₁₅)C(O)-, -N(R₁₅)CON(R₁₆)-, -N(R₁₅)C(O)O-, -OC(O)N(R₁₅)-, -N(R₁₅)SO₂-, -SO₂N(R₁₅)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O)₂-, -N(R₁₅)SO₂N(R₁₆)-, -N=N-, or -N(R₁₅)-N(R₁₆)-,



wherein

R₁₄, R₁₅, and R₁₆ are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl

Ar₂ is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q-R₁₇;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L₆-aryl;
- o) -L₆-arylene-aryl;
- p) -L₆-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;
- x) -Q-arylene-arylene-aryl;
- y) -Q-alkylene-arylene-alkyl;
- z) -L₆-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L₆-Q-aryl;
- cc) -L₆-Q-heteroaryl;
- dd) -L₆-Q-cycloalkyl;
- ee) -L₆-Q-heterocyclyl;
- ff) -L₆-Q-arylene-alkyl;

gg) -L₆-Q-alkylene-arylene-alkyl;
 hh) -L₆-Q-alkyl;
 ii) -L₆-Q-alkylene-aryl-R₁₇;
 jj) -L₆-Q-alkylene-heteroaryl-R₁₇;
 kk) -arylene-Q-alkylene-R₁₇;
 ll) -heteroarylene-Q-alkylene-R₁₇;
 mm) -L₆-Q-aryl-R₁₇;
 nn) -L₆-Q-heteroarylene-R₁₇;
 oo) -L₆-Q-heteroaryl-R₁₇;
 pp) -L₆-Q-cycloalkyl-R₁₇;
 qq) -L₆-Q-heterocyclyl-R₁₇;
 rr) -L₆-Q-arylene-alkyl-R₁₇;
 ss) -L₆-Q-heteroarylene-alkyl-R₁₇;
 tt) -L₆-Q-alkylene-arylene-alkyl-R₁₇;
 uu) -L₆-Q-alkylene-heteroarylene-alkyl-R₁₇;
 vv) -L₆-Q-alkylene-cycloalkylene-alkyl-R₁₇;
 ww) -L₆-Q-alkylene-heterocyclylene-alkyl-R₁₇;
 xx) -L₆-Q-alkyl-R₁₇;
 yy) -L₆-Q-R₁₇;
 zz) -arylene-Q-R₁₇;
 aaa) -heteroarylene-Q-R₁₇;
 bbb) -heterocyclylene-Q-R₁₇;
 ccc) -Q-alkylene-R₁₇;
 ddd) -Q-arylene-R₁₇;
 eee) -Q-heteroarylene-R₁₇;
 fff) -Q-alkylene-arylene-R₁₇;
 ggg) -Q-alkylene-heteroarylene-R₁₇;
 hhh) -Q-heteroarylene-alkylene- R₁₇;
 iii) -Q-arylene-alkylene- R₁₇;
 jjj) -Q-cycloalkylene-alkylene- R₁₇;
 kkk) -Q-heterocyclylene-alkylene- R₁₇;
 III) -Q-alkylene-arylene-alkyl- R₁₇;
 mmm) -Q-alkylene-heteroarylene-alkyl- R₁₇;



wherein


L_6 is a direct bond, -alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, $-CH_2-$, $-O-$, $-N(R_{18})-$, $-C(O)-$, $-CON(R_{18})-$, $-N(R_{18})C(O)-$, $-N(R_{18})CON(R_{19})-$, $-N(R_{18})C(O)O-$, $-OC(O)N(R_{18})-$, $-N(R_{18})SO_2-$, $-SO_2N(R_{18})-$, $-C(O)-O-$, $-O-C(O)-$, $-S-$, $-S(O)-$, $-S(O_2)-$, $-N(R_{18})SO_2N(R_{19})-$, $-N=N-$, or $-N(R_{18})-N(R_{19})-$;

wherein

R_{18} and R_{19} are independently selected from the group consisting of: -
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and
-alkylene-arylene-alkyl;

V is



Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R_{17} is $-SO_3H$, $-P(O)(OH)_2$, $-P(O)(O-alkyl)(OH)$, $-CO_2H$, $-CO_2$ -alkyl, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl


L_2 is a direct bond,


T is a phenyl group optionally substituted 1 to 5 times wherein the substituents are independently selected from the group consisting of

- a) -fluoro;
- b) -chloro;

- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -U-R₂₂;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L₇-aryl;
- o) -L₇-arylene-aryl;
- p) -L₇-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -U-alkyl;
- t) -U-aryl;
- u) -U-alkylene-aryl;
- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L₇-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L₇-U-aryl;
- cc) -L₇-U-heteroaryl;
- dd) -L₇-U-cycloalkyl;
- ee) -L₇-U-heterocyclyl;
- ff) -L₇-U-arylene-alkyl;
- gg) -L₇-U-alkylene-arylene-alkyl;
- hh) -L₇-U-alkyl;
- ii) -L₇-U-alkylene-aryl- R₂₂;
- jj) -L₇-U-alkylene-heteroaryl- R₂₂;

- kk) -arylene-U-alkylene- R_{22} ;
 ll) -heteroarylene-U-alkylene- R_{22} ;
 mm) - L_7 -U-aryl- R_{22} ;
 nn) - L_7 -U-heteroarylene- R_{22} ;
 oo) - L_7 -U-heteroaryl- R_{22} ;
 pp) - L_7 -U-cycloalkyl- R_{22} ;
 qq) - L_7 -U-heterocyclyl- R_{22} ;
 rr) - L_7 -U-arylene-alkyl- R_{22} ;
 ss) - L_7 -U-heteroarylene-alkyl- R_{22} ;
 tt) - L_7 -U-alkylene-arylene-alkyl- R_{22} ;
 uu) - L_7 -U-alkylene-heteroarylene-alkyl- R_{22} ;
 vv) - L_7 -Q-alkylene-cycloalkylene-alkyl- R_{22} ;
 ww) - L_7 -Q-alkylene-heterocyclylene-alkyl- R_{22} ;
 xx) - L_7 -U-alkyl- R_{22} ;
 yy) - L_7 -U- R_{22} ;
 zz) -arylene-U- R_{22} ;
 aaa) -heteroarylene-U- R_{22} ;
 bbb) -heterocyclylene-U- R_{22} ;
 ccc) -U-alkylene- R_{22} ;
 ddd) -U-arylene- R_{22} ;
 eee) -U-heteroarylene- R_{22} ;
 fff) -U-alkylene-arylene- R_{22} ;
 ggg) -U-alkylene-heteroarylene- R_{22} ;
 hhh) -U-heteroarylene-alkylene- R_{22} ;
 iii) -U-arylene-alkylene- R_{22} ;
 jjj) -U-cycloalkylene-alkylene- R_{22} ;
 kkk) -U-heterocyclylene-alkylene- R_{22} ;
 III) -U-alkylene-arylene-alkyl- R_{22} ;
 mmm) -U-alkylene-heteroarylene-alkyl- R_{22} ;





wherein


L_7 is a direct bond, -alkylene, -alkenylene, or -alkynylene;

U is a direct bond, -CH₂-, -O-, -N(R₂₃)-, -C(O)-, -CON(R₂₃)-, -N(R₂₃)C(O)-, -N(R₂₃)CON(R₂₄)-, -N(R₂₃)C(O)O-, -OC(O)N(R₂₃)-, -N(R₂₃)SO₂-, -SO₂N(R₂₃)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O₂)-, -N(R₂₃)SO₂N(R₂₄)-, -N=N-, or -N(R₂₃)-N(R₂₄)-;

wherein

R₂₃ and R₂₄ are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

X is



Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R₂₂ is -SO₃H, -P(O)(OH)₂, -P(O)(O-alkyl)(OH), -CO₂H, -CO₂-alkyl, an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

2. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is -N(R₂)-, wherein R₂ is alkyl, or -L₃-D-alkylene-aryl, wherein L₃ is alkylene, and D is -CO(NR₅)-, wherein R₅ is hydrogen.

3. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R₁ is hydrogen or aryl.

4. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R₁ is hydrogen.

5-6. (Canceled)

7. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₁ is a phenyl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -J-R_{1,4};
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L₅-aryl;
- o) -L₆-arylene-aryl;
- p) -L₆-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -J-alkyl;
- t) -J-aryl;
- u) -J-alkylene-aryl;
- v) -J-arylene-alkyl;
- w) -J-alkylene-arylene-aryl;
- x) -J-arylene-arylene-aryl;
- y) -J-alkylene-arylene-alkyl;

- z) - L₅-J-alkylene-aryl;
- aa) -arylene-J-alkyl;
- bb) - L₅-J-aryl;
- cc) - L₅-J-heteroaryl;
- dd) - L₅-J-cycloalkyl;
- ee) - L₅-J-heterocyclyl;
- ff) - L₅-J-arylene-alkyl;
- gg) - L₅-J-alkylene-arylene-alkyl;
- hh) - L₅-J-alkyl;
- ii) - L₅-J-R₁₄; and
- jj) -arylene-J-R₁₄;

wherein

L₅ is a direct bond, -alkylene, -alkenylene, or -alkynylene;

J is a direct bond, -CH₂-, -O-, -N(R₁₅)-, -C(O)-, -CON(R₁₅)-, -N(R₁₅)C(O)-, -N(R₁₅)CON(R₁₆)-, -N(R₁₅)C(O)O-, -OC(O)N(R₁₅)-, -N(R₁₅)SO₂-, -SO₂N(R₁₅)-, -C(O)-O-, -O-C(O)-, -S-, -S(O)-, -S(O)₂-, -N(R₁₅)SO₂N(R₁₆)-, -N=N-, or -N(R₁₅)-N(R₁₆)-,

wherein

R₁₄, R₁₅, and R₁₆ are independently selected from a group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl.

8. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₁ is a phenyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:



- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro; and
- g) -aryl.

9. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₁ is a phenyl group substituted 1 to 5 times, wherein the substituents are selected from the group consisting of: -chloro and -fluoro.

10. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar₂ is a phenylene group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -Q-R₁₇;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) -L₆-aryl;
- o) -L₆-arylene-aryl;
- p) -L₆-arylene-alkyl;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) -Q-alkyl;
- t) -Q-aryl;
- u) -Q-alkylene-aryl;
- v) -Q-arylene-alkyl;
- w) -Q-alkylene-arylene-aryl;
- x) -Q-arylene-arylene-aryl;

- y) -Q-alkylene-arylene-alkyl;
- z) -L₆-Q-alkylene-aryl;
- aa) -arylene-Q-alkyl;
- bb) -L₆-Q-aryl;
- cc) -L₆-Q-heteroaryl;
- dd) -L₆-Q-cycloalkyl;
- ee) -L₆-Q-heterocyclyl;
- ff) -L₆-Q-arylene-alkyl;
- gg) -L₆-Q-alkylene-arylene-alkyl;
- hh) -L₆-Q-alkyl;
- ii) -L₆-Q-alkylene-aryl-R₁₇;
- jj) -L₆-Q-alkylene-heteroaryl-R₁₇;
- kk) -arylene-Q-alkylene-R₁₇;
- ll) -heteroarylene-Q-alkylene-R₁₇;
- mm) -L₆-Q-aryl-R₁₇;
- nn) -L₆-Q-heteroarylene-R₁₇;
- oo) -L₆-Q-heteroaryl-R₁₇;
- pp) -L₆-Q-cycloalkyl-R₁₇;
- qq) -L₆-Q-heterocyclyl-R₁₇;
- rr) -L₆-Q-arylene-alkyl-R₁₇;
- ss) -L₆-Q-heteroarylene-alkyl-R₁₇;
- tt) -L₆-Q-alkylene-arylene-alkyl-R₁₇;
- uu) -L₆-Q-alkylene-heteroarylene-alkyl-R₁₇;
- vv) -L₆-Q-alkylene-cycloalkylene-alkyl-R₁₇;
- ww) -L₆-Q-alkylene-heterocyclylene-alkyl-R₁₇;
- xx) -L₆-Q-alkyl-R₁₇;
- yy) -L₆-Q-R₁₇;
- zz) -arylene-Q-R₁₇;
- aaa) -heteroarylene-Q-R₁₇;
- bbb) -heterocyclylene-Q-R₁₇;
- ccc) -Q-alkylene-R₁₇;
- ddd) -Q-arylene-R₁₇;
- eee) -Q-heteroarylene-R₁₇;
- fff) -Q-alkylene-arylene-R₁₇;

ggg) -Q-alkylene-heteroarylene- R_{17} ;hhh) -Q-heteroarylene-alkylene- R_{17} ;iii) -Q-arylene-alkylene- R_{17} ;jjj) -Q-cycloalkylene-alkylene- R_{17} ;kkk) -Q-heterocyclylene-alkylene- R_{17} lll) -Q-alkylene-arylene-alkyl- R_{17} ;mmm) -Q-alkylene-heteroarylene-alkyl- R_{17} ;

wherein


 L_6 is a direct bond, -alkylene, -alkenylene, or -alkynylene;

Q is a direct bond, $-CH_2-$, $-O-$, $-N(R_{18})-$, $-C(O)-$, $-CON(R_{18})-$, $-N(R_{18})C(O)-$, $-N(R_{18})CON(R_{19})-$, $-N(R_{18})C(O)O-$, $-OC(O)N(R_{18})-$, $-N(R_{18})SO_2-$, $-SO_2N(R_{18})-$, $-C(O)-O-$, $-O-C(O)-$, $-S-$, $-S(O)-$, $-S(O_2)-$, $-N(R_{18})SO_2N(R_{19})-$, $-N=N-$, or $-N(R_{18})-N(R_{19})-$;

wherein

R_{18} and R_{19} are independently selected from the group consisting of: -
hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and
-alkylene-arylene-alkyl;

V is



Z is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R_{17} is $-\text{SO}_3\text{H}$, $-\text{P}(\text{O})(\text{OH})_2$, $-\text{P}(\text{O})(\text{O-alkyl})(\text{OH})$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{-alkyl}$, an acid isostere, hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

11. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenyl group optionally substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q- R_{17} ;
- f) -alkyl;
- g) -aryl;
- h) -arylene-alkyl;
- i) -Q-alkyl; and
- j) -arylene-Q-alkyl;

wherein

Q is $-\text{CH}_2-$, $-\text{O}-$, $-\text{C}(\text{O})-$, or $-\text{C}(\text{O})-\text{O}-$, and

R_{17} is: -hydrogen, -alkyl, -aryl, $-\text{CO}_2\text{H}$, or an acid isostere.

12. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_2 is a phenyl group substituted 1 to 5 times, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -Q- R_{17} ;
- f) -alkyl;

- g) -phenyl;
- h) -phenylene-alkyl;
- i) -Q-alkyl; and
- j) -phenylene-Q-alkyl;

wherein

Q is: $-\text{CH}_2-$, $-\text{O}-$, $-\text{C}(\text{O})-$, or $-\text{C}(\text{O})-\text{O}-$, and

R_{17} is: -hydrogen, -alkyl, -phenyl, or $-\text{CO}_2\text{H}$.



13-15. (Canceled)

16. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein T is an aryl group having 1 to 5 substituents, wherein the substituents are independently selected from the group consisting of:

- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) $-\text{U}-\text{R}_{22}$;
- i) -alkyl;
- j) -aryl;
- k) -heteroaryl;
- l) -heterocyclyl;
- m) -cycloalkyl;
- n) $-\text{L}_7\text{-aryl}$;
- o) $-\text{L}_7\text{-arylene-aryl}$;
- p) $-\text{L}_7\text{-arylene-alkyl}$;
- q) -arylene-alkyl;
- r) -arylene-arylene-alkyl;
- s) $-\text{U-alkyl}$;

- t) -U-aryl;
- u) -U-alkylene-aryl;
- v) -U-arylene-alkyl;
- w) -U-alkylene-arylene-aryl;
- x) -U-arylene-arylene-aryl;
- y) -U-alkylene-arylene-alkyl;
- z) -L₇-U-alkylene-aryl;
- aa) -arylene-U-alkyl;
- bb) -L₇-U-aryl;
- cc) -L₇-U-heteroaryl;
- dd) -L₇-U-cycloalkyl;
- ee) -L₇-U-heterocyclyl;
- ff) -L₇-U-arylene-alkyl;
- gg) -L₇-U-alkylene-arylene-alkyl;
- hh) -L₇-U-alkyl;
- ii) -L₇-U-alkylene-aryl- R₂₂;
- jj) -L₇-U-alkylene-heteroaryl- R₂₂;
- kk) -arylene-U-alkylene- R₂₂;
- ll) -heteroarylene-U-alkylene- R₂₂;
- mm) -L₇-U-aryl- R₂₂;
- nn) -L₇-U-heteroarylene- R₂₂;
- oo) -L₇-U-heteroaryl- R₂₂;
- pp) -L₇-U-cycloalkyl- R₂₂;
- qq) -L₇-U-heterocyclyl- R₂₂;
- rr) -L₇-U-arylene-alkyl- R₂₂;
- ss) -L₇-U-heteroarylene-alkyl- R₂₂;
- tt) -L₇-U-alkylene-arylene-alkyl- R₂₂;
- uu) -L₇-U-alkylene-heteroarylene-alkyl- R₂₂;
- vv) -L₇-Q-alkylene-cycloalkylene-alkyl-R₂₂;
- ww) -L₇-Q-alkylene-heterocyclylene-alkyl-R₂₂;
- xx) -L₇-U-alkyl- R₂₂;
- yy) -L₇-U- R₂₂;
- zz) -arylene-U- R₂₂;
- aaa) -heteroarylene-U- R₂₂;

- bbb) -heterocyclylene-U- R_{22} ;
 ccc) -U-alkylene- R_{22} ;
 ddd) -U-arylene- R_{22} ;
 eee) -U-heteroarylene- R_{22} ;
 fff) -U-alkylene-arylene- R_{22} ;
 ggg) -U-alkylene-heteroarylene- R_{22} ;
 hhh) -U-heteroarylene-alkylene- R_{22} ;
 iii) -U-arylene-alkylene- R_{22} ;
 jjj) -U-cycloalkylene-alkylene- R_{22} ;
 kkk) -U-heterocyclylene-alkylene- R_{22} ;
 III) -U-alkylene-arylene-alkyl- R_{22} ;
 mmm) -U-alkylene-heteroarylene-alkyl- R_{22} ;



wherein


L_7 is a direct bond, -alkylene, -alkenylene, or -alkynylene;

U is a direct bond, $-CH_2-$, $-O-$, $-N(R_{23})-$, $-C(O)-$, $-CON(R_{23})-$, $-N(R_{23})C(O)-$, $-N(R_{23})CON(R_{24})-$, $-N(R_{23})C(O)O-$, $-OC(O)N(R_{23})-$, $-N(R_{23})SO_2-$, $-SO_2N(R_{23})-$, $-C(O)O-$, $-O-C(O)-$, $-S-$, $-S(O)-$, $-S(O_2)-$, $-N(R_{23})SO_2N(R_{24})-$, $-N=N-$, or $-N(R_{23})-N(R_{24})-$;

wherein

R_{23} and R_{24} are independently selected from the group consisting of: -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;

X is




Y is hydrogen, -alkylene-aryl, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -cycloalkyl, -alkylene-heteroaryl, or -alkylene-cycloalkyl;

R₂₂ is -SO₃H, -P(O)(OH)₂, -P(O)(O-alkyl)(OH), -CO₂H, -CO₂-alkyl, an acid isostere, -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl.

17. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein T is an aryl group substituted by -U-alkylene-R₂₂, wherein U is -O- or a direct bond, and R₂₂ is -CO₂H or an acid isostere.

18. (Currently Amended) The compound of Formula (I) according to claim 16 or a pharmaceutically acceptable salt or solvate thereof, wherein

a and b are equal to zero;



Ar₂ is a phenylene group optionally substituted 1 time with a group consisting of:
-Q-alkyl, wherein Q is -O-;

L₂ is a direct bond; and

T is an aryl group substituted with at least one substituent selected from the group consisting of:

- a) -U-R₂₂;
- b) -U-alkylene-arylene-R₂₂;
- c) -U-alkylene-R₂₂;
- d) -U-arylene-R₂₂;
- e) -U-arylene-R₂₂ wherein the arylene is substituted with at least one of a halogen, methanesulfonylamino, or trifluoromethanesulfonylamino group;
- f) -U-arylene wherein the arylene is substituted with at least one trifluoromethanesulfonylamino group;
- g) -R₂₂; and

h) -halogen;
wherein R_{22} is $-CO_2H$ or an acid isostere.

19. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein

a and b are equal to zero;

R_1 is hydrogen;

W is $-N(R_2)-$, wherein R_2 is alkyl; and

Ar_1 is phenyl substituted 2 times wherein the substituent groups are $-chloro$.

20. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein W is $-N(R_2)-$, wherein

R_2 is -alkylene-arylene-G,

wherein

G is $-CN$, $-SO_3H$, $-P(O)(OH)_2$, $-P(O)(O-alkyl)(OH)$, $-CO_2H$, $-CO_2-$ alkyl, or an acid isostere.

21. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein a and b are equal to 0, and T, L_2 , Ar_2 , and L_1 together form a group selected from a group consisting of:

(E)-2-(1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-methoxy-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(3'-methoxy-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-carboxymethoxy-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-(3-methoxycarbonyl-1-propyloxy)-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-(3-carboxy-1-propyloxy)-1,1'-biphenyl-4-yl)vinyl,

(E)-2-(4'-phenoxy-1,1'-biphenyl-4-yl)vinyl, and

(E)-2-(4'-benzyloxy-1,1'-biphenyl-4-yl)vinyl.

22. (Currently Amended) The compound of Formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein Ar_1 is: 2,4-dichlorophenyl.

23. (Currently Amended) The compound of Formula (I) according to claim 1, where the compound of Formula (I) is:

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-3-fluoro-biphenyl-4-yloxy-methyl)-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-[(1-naphthalen-1-yl-ethylcarbamoyl)-methyl] 1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-butyric acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-butyric acid;

5-(4'-(2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-pentanoic acid

2-bromo-4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-methyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy-methyl)-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-benzoic acid;

2-bromo-4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-3-methanesulfonylamino-benzoic acid;

4-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-3-trifluoromethanesulfonyl-amino-benzoic acid;

5-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-2-methanesulfonylamino-benzoic acid;

5-(4'-(2-[4-(2,4-dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-2-trifluoromethane-sulfonylamino-benzoic acid; or

4-(4'-(2-[4-(2,4-Dichloro-phenyl)-1-ethyl-1H-imidazol-2-yl]-(E)-vinyl)-biphenyl-4-yloxy)-butyric acid 2,2-dimethyl-propionyloxymethyl ester,

or a pharmaceutically acceptable salt or solvate thereof.

24. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1.

25. (Previously Presented) The pharmaceutical composition of claim 24, wherein said pharmaceutical composition is a topical formulation.

26-31. (Canceled).

32. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type I diabetes.

33. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat type II diabetes.

34-37. (Canceled).

38. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat obesity.

39. (Canceled).

40. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmacologically effective amount of the compound as claimed in claim 1, sufficient to treat psoriasis.

41-63. (Canceled).